Business ❯ Healthcare ❯ Pharmaceuticals

Clinical Trials

Drug Development Oncology Drug Safety Safety Regulations Product Compliance Obesity Treatments Regulatory Compliance Drug Efficacy Regulatory Approval Product Candidates Phase 3 Trials Companion Diagnostics Product Development RAP-219 Program Multiple Myeloma AI in Drug Development Jasper Therapeutics Kidney Disease siRNA Treatments Investor Relations Investigational Drugs Choroidal Melanoma VX-993 Market Competition Cemdisiran Safety Concerns Osteogenesis Imperfecta Regulatory Approvals Phase 1 Trial Drug Candidates COVID-19 Treatments Pulmonary Arterial Hypertension COPD Treatment Type 2 Diabetes MariTide Hyalofast DESTINY-Breast05 Cancer Treatments Duchenne Muscular Dystrophy BMS and J&J Blood Thinner Phase 3 Results Therapeutics Cardiovascular Therapies Essential Tremor Amgen In Vivo CAR-T Programs ADEPT-2 Study Social Anxiety Disorder AI in Healthcare Major Depressive Disorder Pemvidutide Breast Cancer Immunotherapy AstraZeneca

Ford Energy Strikes Five-Year EDF Deal for Up to 20 GWh of Grid Batteries

The agreement signals a pivot into U.S.-assembled battery storage for large power users.

Regeneron Slides as Melanoma Combo Fails to Beat Keytruda in Phase 3

Legend Biotech Q1 Sales Jump on CARVYKTI Growth Despite Expansion-Related Margin Hit

Roche to Acquire PathAI for $750 Million Upfront Plus Up to $300 Million in Milestones

AstraZeneca Tops Q1 Forecasts, Reaffirms 2026 Outlook as Oncology Fuels Growth

Gossamer Bio Investors Sought to Lead Lawsuit After Seralutinib Trial Failure

Soleno Therapeutics Investors Face May 5 Deadline to Seek Lead Role in Securities Class Action

Law Firms Press Soleno Investors to Seek Lead Role in Securities Suit by May 5

Soleno Faces Securities Class Action Over DCCR Safety as Investors Weigh May 5 Lead‑Plaintiff Deadline

Soleno Hit With Securities Class Action Over Prader‑Willi Drug DCCR

Sarepta Reports Early siRNA Data Showing Muscle Delivery as Shares Surge

Wave Life Sciences Shares Plunge 30% After Early Obesity Trial Readout

Plaintiff Firms Intensify Biotech Securities Suits as Key Deadlines Near for Nektar, uniQure and REGENXBIO

Law Firms Seek Soleno Investors Ahead of May 5 Lead‑Plaintiff Deadline

Law Firms Urge Nektar Investors to Seek Lead Role in Securities Suit Over REZOLVE-AA Trial

Soleno Therapeutics Sued in Federal Securities Class Action Over DCCR Safety and Launch Claims

Vistagen Investors Urged to Seek Lead Plaintiff Role in Securities Suit as March 16 Deadline Nears

Vistagen Hit With Securities Class Actions After Phase 3 Miss as Investors Face March 16 Deadline

Vistagen Faces Federal Securities Class Action After Fasedienol Phase 3 Failure

Alumis TYK2 Pill Hits Phase 3 Goals in Psoriasis as Stock Jumps and $175 Million Offering Is Planned